Leaps by Bayer co-led an oversubscribed round for the oncology therapeutics developer, with the proceeds to go to clinical trials and supplementary licences.

US-based cancer therapy developer Affini-T Therapeutics closed an oversubscribed $175m round yesterday co-led by Leaps by Bayer, a subsidiary of pharmaceutical and chemicals group Bayer.

Life sciences-focused investment firm Vida Ventures co-led the round, which included Alexandria Venture Investments, a vehicle for life sciences and property investment trust Alexandria Real Estate Equities.

Humboldt Fund, The Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Agent Capital, Erasca Ventures, Fred Hutchinson Cancer Research Center and unnamed others filled out the participants in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn